Syros Pharmaceuticals, Inc. Company Analysis & Research
Syros Pharmaceuticals is a biopharmaceutical company focused on the development of treatment for hematologic malignancies. The company operates within the biopharmaceutical sector, focusing on the development of treatments that control the expression of genes to address the root causes of diseases, leveraging its proprietary gene control platform to design therapies for cancer and monogenic diseases.
Lead product candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III clinical trial for myelodysplastic syndrome and Phase II for acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I clinical trial. The company is navigating significant development challenges following recent clinical trial setbacks.
Company Overview
Founded: 2011. Headquarters: Cambridge, Massachusetts. Revenue: $0.39M. Market Cap: $0.68M. Ticker: SYRS (NASDAQ).
Industry
Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics
Cyborg Score: 3/10 — Challenged
Biotech company at critical inflection point following failed flagship trial and planned Nasdaq delisting, facing significant execution risk despite innovative gene control platform.
The Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve its primary endpoint of complete response rate. Syros plans to voluntarily delist its common stock from Nasdaq and deregister to terminate its reporting obligations under the Exchange Act. The company faces existential challenges with minimal revenue and substantial operating losses.
Key Strategic Insights for Syros Pharmaceuticals, Inc.
- Phase 3 SELECT-MDS-1 trial of tamibarotene failed to achieve primary endpoint - major setback for lead program
- Company plans voluntary delisting from Nasdaq and deregistration - signals reduced transparency and financial stress
- Leverages proprietary gene control platform to design therapies for cancer and monogenic diseases - differentiated technology approach
- Rege Nephro acquired Tamibarotene-related clinical and non-clinical assets from Syros through mutual agreement - recent asset divestiture
Recent Developments
- (2024) SELECT-MDS-1 Phase 3 trial failure - Tamibarotene did not meet primary endpoint
- (2024) Announced planned voluntary delisting from Nasdaq
- (2024) Asset sale - Tamibarotene assets transferred to Rege Nephro
- (2024) Multiple shareholder litigation investigations announced
Competitors & Competitive Landscape
- Gilead Sciences — Established cancer therapeutic portfolio
- Celgene/Bristol Myers Squibb — Market leader in multiple myeloma and related conditions
- Sangamo Therapeutics — Gene control and editing platform company
Syros competes in the hematologic malignancy and gene control therapeutic space against large pharma and other biotech companies. The company's gene control platform represents a differentiated approach, but recent clinical failures have undermined competitive positioning. Key competitors include larger oncology-focused pharmaceutical companies with more established development pipelines and financial resources.
More Company Research
Third Harmonic Bio Lineage Cell Therapeutics, Inc. MeiraGTx Holdings plc Varroc Engineering Limited Is Yatirim Menkul Degerler Anonim Sirketi Meliá Hotels International, S.A. Port of Tauranga Limited Inpex Corporation Cirrus Logic, Inc. HF Sinclair Corporation Unity Software Inc. Commerzbank AG eFFECTOR Therapeutics, Inc. Mentice AB Al Anwar Ceramic TilesFull Company Research Reports
Looking for a more in-depth analysis of Syros Pharmaceuticals, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, analyst debate audio, and saved-company audio playlists.